Novo Nordisk Stock Reaches Record High after Positive Drug Test Results

Novo Nordisk’s stock rose by 8% on March 7th, reaching a new all-time high. The Danish pharmaceutical giant reported positive trial data for its new weight-loss drug, which is expected to alleviate concerns about weight gain. The trial results showed outstanding effectiveness, surpassing expectations.

Promising Test Results for Weight-Loss Drug

During a meeting with investors, Novo Nordisk revealed that the phase I trial of its amycretin obesity treatment showed a 13.1% weight reduction after 12 weeks. This is a remarkable improvement compared to the 6% reduction observed with Wegovy, the company’s popular anti-obesity drug. The phase II trial is scheduled to begin in the second half of this year, with results expected in early 2026.

Novo Nordisk’s Market Performance

Novo Nordisk, the largest European company by market capitalization, has already seen a 27% increase in its stock value since the beginning of the year. The company continues to benefit from the high demand for its leading anti-obesity drugs, Wegovy and Ozempic.

Earlier this week, Novo reported final stage trial results showing that Ozempic reduces the risk of kidney disease progression and death from kidney or cardiovascular complications in patients with diabetes and chronic kidney disease. These results provide further evidence of the significant health benefits associated with Ozempic and similar drugs, beyond weight loss and type 2 diabetes treatment.

Yury Khodjamirian, an investment director at Tema ETFs, stated, “Safety is a key factor, and Novo is waiting for the subcutaneous injection formula’s results before planning clinical trials. We believe this will strengthen Novo’s position, as the company currently has several agents connecting with Ozempic/Wegovy to carry out licensing activities.”

Eli Lilly’s Stock Reaction

Novo Nordisk’s news had a negative impact on the stock of its American counterpart, Eli Lilly, which decreased by 0.6%.

These positive trial results have propelled Novo Nordisk’s stock to record heights, reinforcing the company’s position as a leader in the pharmaceutical industry. For more financial news and information, visit Business Today.